Skip to main content

Table 3 Distribution of adverse events among study participants

From: Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

 

All

(n = 49), n (%)

Good

(n = 27), n (%)

Poor

(n = 22), n (%)

All

G 1/2

≥G 3

All

G 1/2

≥G 3

All

G 1/2

≥G 3

Fatigue

4 (8)

4 (8)

0

2 (7)

2 (7)

0

2 (9)

2 (9)

0

Pruritis

3 (6)

3 (6)

0

3 (11)

3 (11)

0

0

0

0

Diarrhoea

6 (12)

3 (6)

3 (6)

2 (7)

0

2 (7)

4 (18)

3 (14)

1 (5)

Anorexia

2 (4)

2 (4)

0

1 (4)

1 (4)

0

1 (5)

1 (5)

0

Hypothyroidism

2 (4)

2 (4)

0

1 (4)

1 (4)

0

1 (5)

1 (5)

0

Rash

3 (6)

2 (4)

1 (2)

3 (11)

2 (7)

1 (4)

0

0

0

Hyperglycaemia

1 (2)

0

1 (2)

1 (4)

0

1 (4)

0

0

0

Liver dysfunction

1 (2)

1 (2)

0

0

0

0

1 (5)

1 (5)

0

Adrenal insufficiency

2 (4)

2 (4)

0

2 (7)

2 (7)

0

0

0

0

Stomatitis

1 (2)

1 (2)

0

1 (4)

1 (4)

0

0

0

0

Fever

1 (2)

1 (2)

0

1 (4)

1 (4)

0

0

0

0